FarmaKology -New drug offers hope for pancreatic cancer patients

Nov 11, 2021

Today's Company

Arbor Biotechnologies

Arbor Biotechnologies is an early stage life sciences company pushing the boundaries of biodiscovery. Arbor’s platform employs a diverse set of technologies and techniques – including artificial intelligence, genome sequencing, gene synthesis and high-throughput screening – for accelerating the discovery of proteins for improving human health and sustainability.

News

Merck and Ridgeback Announce Japanese Government to Purchase 1.6 Million Courses of Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, Upon Authorization or Approval

Merck , known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the Japanese government will purchase, upon authorization or approval, approximately 1.6 million courses of molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine. Merck is developing molnupiravir in collaboration with Ridgeback Biotherapeutics. Merck’s applications for the potential authorized use of molnupiravir are under review by Japan’s Pharmaceuticals and Medical Devices Agency, the U.S. Food and Drug Administration, and the European Medicines Agency. Molnupiravir is authorized in the United Kingdom for the treatment of mild-to-moderate COVID-19 in adults with a positive SARS-CoV-2 diagnostic test and who have at least one risk factor for developing severe illness.

Notable Launches Therapeutic Pipeline by Acquiring Worldwide Development and Commercialization Rights to Volasertib

Notable Labs, Inc. , a pioneer and developer of predictive precision medicines, has obtained worldwide rights to volasertib from Oncoheroes Biosciences Inc., a Boston-based biotechnology company focused on advancing new therapies for childhood cancer. Volasertib is a Polo-like kinase 1 (PLK-1) inhibitor with demonstrated activity in acute myeloid leukemia (AML) and other tumor types with significant unmet medical need.

Wegovy™ recommended for approval for the treatment of obesity by the European regulatory authorities

Novo Nordisk today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending marketing authorisation for Wegovy™ for chronic weight management in adults with obesity.Wegovy™ is a once-weekly semaglutide 2.4 mg injection for chronic weight management in adults living with obesity (initial BMI≥30 kg/m2) or overweight (initial BMI≥27 kg/m2) with at least one weight-related comorbidity such as high blood pressure, heart disease or type 2 diabetes.

AffaMed Therapeutics Announces the Establishment of AffaMed Digital to Advance Digital Medicines

AffaMed Therapeutics , a global clinical-stage therapeutic company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmic, neurological and psychiatric disorders, today announced the establishment of AffaMed Digital. As a wholly owned subsidiary of AffaMed, the new AffaMed Digital will focus on the development and commercialization of evidence-based, clinically validated digital medicines to treat, diagnose, prevent, and/or manage medical disorders or diseases, either as stand-alone novel treatment options, or in concert with other therapies to optimize patient care and health outcomes.